A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

R B Buchanan; R W Blamey; K R Durrant; A Howell; A G Paterson; P E Preece; D C Smith; C J Williams; R G Wilson

doi:10.1200/JCO.1986.4.9.1326

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

R B Buchanan, R W Blamey, K R Durrant, A Howell, A G Paterson, P E Preece, D C Smith, C J Williams, R G Wilson

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.

Original language	English
Pages (from-to)	1326-1330
Number of pages	5
Journal	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume	4
Issue number	9
DOIs	https://doi.org/10.1200/JCO.1986.4.9.1326
Publication status	Published - Sept 1986

Keywords

Adult
Breast Neoplasms
Clinical Trials as Topic
Female
Humans
Middle Aged
Neoplasm Metastasis
Oligomenorrhea
Ovariectomy
Random Allocation
Receptors, Estrogen
Tamoxifen
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.1986.4.9.1326

Cite this

Buchanan, R. B., Blamey, R. W., Durrant, K. R., Howell, A., Paterson, A. G., Preece, P. E., Smith, D. C., Williams, C. J., & Wilson, R. G. (1986). A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 4(9), 1326-1330. https://doi.org/10.1200/JCO.1986.4.9.1326

@article{21c62b9033fd444e858d1155788fa3c4,

title = "A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer",

abstract = "We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.",

keywords = "Adult, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Middle Aged, Neoplasm Metastasis, Oligomenorrhea, Ovariectomy, Random Allocation, Receptors, Estrogen, Tamoxifen, Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial",

author = "Buchanan, {R B} and Blamey, {R W} and Durrant, {K R} and A Howell and Paterson, {A G} and Preece, {P E} and Smith, {D C} and Williams, {C J} and Wilson, {R G}",

year = "1986",

month = sep,

doi = "10.1200/JCO.1986.4.9.1326",

language = "English",

volume = "4",

pages = "1326--1330",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "9",

}

Buchanan, RB, Blamey, RW, Durrant, KR, Howell, A, Paterson, AG, Preece, PE, Smith, DC, Williams, CJ & Wilson, RG 1986, 'A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 4, no. 9, pp. 1326-1330. https://doi.org/10.1200/JCO.1986.4.9.1326

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. / Buchanan, R B; Blamey, R W; Durrant, K R et al.
In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 4, No. 9, 09.1986, p. 1326-1330.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

AU - Buchanan, R B

AU - Blamey, R W

AU - Durrant, K R

AU - Howell, A

AU - Paterson, A G

AU - Preece, P E

AU - Smith, D C

AU - Williams, C J

AU - Wilson, R G

PY - 1986/9

Y1 - 1986/9

N2 - We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.

AB - We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.

KW - Adult

KW - Breast Neoplasms

KW - Clinical Trials as Topic

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Oligomenorrhea

KW - Ovariectomy

KW - Random Allocation

KW - Receptors, Estrogen

KW - Tamoxifen

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1200/JCO.1986.4.9.1326

DO - 10.1200/JCO.1986.4.9.1326

M3 - Article

C2 - 3528402

SN - 0732-183X

VL - 4

SP - 1326

EP - 1330

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

IS - 9

ER -

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this